Maribavir
| Title | Journal |
|---|---|
| The unique antiviral activity of artesunate is broadly effective against human cytomegaloviruses including therapy-resistant mutants. | Antiviral research 20111101 |
| Genotypic characterization of human cytomegalovirus UL97 phosphotransferase natural polymorphism in the era of ganciclovir and maribavir. | Antiviral research 20110701 |
| Antiviral inhibition targeting the HCMV kinase pUL97 requires pUL27-dependent degradation of Tip60 acetyltransferase and cell-cycle arrest. | Cell host & microbe 20110217 |
| Oral maribavir for treatment of refractory or resistant cytomegalovirus infections in transplant recipients. | Transplant infectious disease : an official journal of the Transplantation Society 20101201 |
| Leflunomide: a small step forward in meeting the urgent need for treatment of drug-resistant cytomegalovirus infection. | Transplantation 20100827 |
| Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir. | The Journal of infectious diseases 20100701 |
| Antiviral prophylaxis in haematological patients: systematic review and meta-analysis. | European journal of cancer (Oxford, England : 1990) 20091201 |
| A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. | American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 20091001 |
| Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. | Reviews in medical virology 20090701 |
| Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir. | Virology journal 20090101 |
| Viral mimicry of Cdc2/cyclin-dependent kinase 1 mediates disruption of nuclear lamina during human cytomegalovirus nuclear egress. | PLoS pathogens 20090101 |
| Conserved domains and structure prediction of human cytomegalovirus UL27 protein. | Antiviral therapy 20090101 |
| Maribavir: a novel antiviral agent with activity against cytomegalovirus. | The Annals of pharmacotherapy 20081001 |
| Cytomegalovirus infection after liver transplantation: current concepts and challenges. | World journal of gastroenterology 20080821 |
| Maribavir prophylaxis for prevention of cytomegalovirus infection in allogeneic stem cell transplant recipients: a multicenter, randomized, double-blind, placebo-controlled, dose-ranging study. | Blood 20080601 |
| Expression of the human cytomegalovirus UL97 gene in a chimeric guinea pig cytomegalovirus (GPCMV) results in viable virus with increased susceptibility to ganciclovir and maribavir. | Antiviral research 20080601 |
| Prevention and early treatment of opportunistic viral infections in patients with leukemia and allogeneic stem cell transplantation recipients. | Journal of the National Comprehensive Cancer Network : JNCCN 20080201 |
| Cytomegalovirus UL97 mutations in the era of ganciclovir and maribavir. | Reviews in medical virology 20080101 |
| Cytomegalovirus UL97 kinase mutations that confer maribavir resistance. | The Journal of infectious diseases 20070701 |
| Pharmacokinetics of maribavir, a novel oral anticytomegalovirus agent, in subjects with varying degrees of renal impairment. | Journal of clinical pharmacology 20070201 |
| Maribavir: 1263W94, Benzimidavir, GW 1263, GW 1263W94, VP41263. | Drugs in R&D 20070101 |
| Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. | Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 20061001 |
| N-methylpurine DNA glycosylase and 8-oxoguanine dna glycosylase metabolize the antiviral nucleoside 2-bromo-5,6-dichloro-1-(beta-D-ribofuranosyl)benzimidazole. | Drug metabolism and disposition: the biological fate of chemicals 20060601 |
| [Therapeutic approach to EBV infection]. | Nihon rinsho. Japanese journal of clinical medicine 20060301 |
| In vitro activity and mechanism of action of methylenecyclopropane analogs of nucleosides against herpesvirus replication. | Antimicrobial agents and chemotherapy 20050301 |
| Inhibition of human cytomegalovirus replication by benzimidazole nucleosides involves three distinct mechanisms. | Antimicrobial agents and chemotherapy 20041001 |
| Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus. | Antimicrobial agents and chemotherapy 20040501 |
| Activities of benzimidazole D- and L-ribonucleosides in animal models of cytomegalovirus infections. | Antimicrobial agents and chemotherapy 20040501 |
| Effects of maribavir and selected indolocarbazoles on Epstein-Barr virus protein kinase BGLF4 and on viral lytic replication. | Antimicrobial agents and chemotherapy 20040501 |
| In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. | Antimicrobial agents and chemotherapy 20030701 |
| Interactions of 1263W94 with other antiviral agents in inhibition of human cytomegalovirus replication. | Antimicrobial agents and chemotherapy 20030401 |
| Resistance of human cytomegalovirus to D- and L-ribosyl benzimidazoles as a tool to identify potential targets for antiviral drugs. | Nucleosides, nucleotides & nucleic acids 20030101 |
| Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus. | Antiviral research 20021001 |
| Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. | Antimicrobial agents and chemotherapy 20020801 |
| Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94. | Clinical and diagnostic laboratory immunology 20011101 |
| A novel nonnucleoside inhibitor specifically targets cytomegalovirus DNA maturation via the UL89 and UL56 gene products. | Journal of virology 20011001 |
| Synthesis and antiviral evaluation of halogenated beta-D- and -L-erythrofuranosylbenzimidazoles. | Journal of medicinal chemistry 20000615 |
| Synthesis and evaluation of a series of 2'-deoxy analogues of the antiviral agent 5,6-dichloro-2-isopropylamino-1-(beta-L-ribofuranosyl)-1H-benzimidazole (1263W94). | Nucleosides, nucleotides & nucleic acids 20000101 |
| Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole. | Journal of virology 19990901 |
| Human cytomegalovirus: challenges, opportunities and new drug development. | Antiviral chemistry & chemotherapy 19990901 |
| Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease. | Advances in experimental medicine and biology 19990101 |